Third Quarter 2024 Financial Results Total revenue for the third quarter of 2024 was $2.0 million, an increase of 34% compared to the prior year period. Sepsis test revenue grew 34% compared to the ...
Research and development expenses were $2.6 million for the three months ended September 30, 2024, compared to $1.1 million for the same period in 2023. The increase was primarily attributable to ...
A PMDA consultation is scheduled to take place in late November as preparation for a subsequent clinical consultation after results from the CardiAMP Heart ... we caution you that forward-looking ...
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated ...
12, 2024 /PRNewswire/ -- Edan Instruments Inc. (300206.SZ), a leading global provider of medical ... which drew widespread attention for its robust performance as a powerful solution for diverse ...
Objective To determine the association between survey-based self-reported problematic low energy availability indicators (LEA-I) and race performance and intra-event medical encounters ... of male ...